All lobbying filings

VIATRIS INC.

Lobbying for VIATRIS INC

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Pennsylvania · House · Senate · $640,000.00 expenses · posted Oct 20, 2025

Official filing document

Bills named in this filing 8

S 891
Bipartisan Health Care Act
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 1302
Increasing Transparency in Generic Drug Applications Act
HR 4132
Prescription Information Modernization Act of 2025
S 2027
Prescription Information Modernization Act of 2025
S 2658
Medication Affordability and Patent Integrity Act
S 2296
National Defense Authorization Act for Fiscal Year 2026
HR 9747
Continuing Appropriations and Extensions Act, 2025

Lobbying activity 6

Health Issues

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering H.R. 1843 / S. 1302 - Increasing Transparency in Generic Drug Applications Act HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S.2658 - The Medication Affordability and Patent Integrity Act

IP Issues related to generic medicines Patent Settlements S 1553, The PREVAIL Act

Trade (domestic/foreign)

Trade issues related to generic medicines Pharmaceutical supply chain

Financial Institutions/Investments/Securities

Policy related to corporate governance

Defense

S.2296 National Defense Authorization Act

Budget/Appropriations

HR 9747 Countinuing Appropriations and Extensions Act of 2025 (Title II, all provisions relating to Health Extenders)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.